Topics
Business & Finance
-
Friday - February 26, 2010
Spring Financial News Conference
Full Year 2009 Results » more
-
Friday - February 26, 2010
Bayer modifies Board of Management compensation system
Reduction of short-term incentive and strengthening of long-term compensation component / Extended share retention period under long-term incentive program / Increased personal investment in Bayer stock / Adjustments effective January 1, 2010 / Compensation system to be submitted to Annual Stockholders’ Meeting for approval » more
-
Wednesday - February 24, 2010
Bayer proposes dividend for 2009 of EUR 1.40 per share » more
-
Thursday - January 28, 2010
Crop Protection portfolio strengthened by further biological product:
Bayer CropScience acquires biofungicide from AgroGreen » more
-
Monday - January 25, 2010
Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis
Study will not be able to meet primary endpoint / Bayer remains committed to developing its long-acting recombinant factor VIII compounds; alternative candidates in development » more
-
Thursday - December 10, 2009
Clinical Programs with Riociguat in Pulmonary Hypertension Well on Track
Encouraging top-line data from the first Phase II study in pulmonary hypertension owing to interstitial lung disease (PH-ILD) / First Phase II study in pulmonary hypertension owing to chronic obstructive pulmonary disease (PH-COPD) successfully completed » more
-
Monday - December 7, 2009
Visanne® cleared for market launch in Europe as new treatment option for endometriosis » more
-
Tuesday - December 1, 2009
Development of new BiTE antibody for treatment of solid tumors:
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy » more
-
Tuesday - December 1, 2009
Bayer’s Betaferon® approved in China for Treatment of Multiple Sclerosis
Launch planned by mid 2010 » more
-
Monday - November 2, 2009
Successful purchase of trait platform with extensive product pipeline:
Bayer CropScience completes acquisition of biotech company Athenix Corp.
Purchase price of USD 365 million plus milestones » more
-
Tuesday - October 27, 2009
News Conference Call for the Third Quarter of 2009
Address by Werner Wenning
Chairman of the Board of Management » more
-
Tuesday - October 27, 2009
Bayer AG News Conference Call and Report for the Third Quarter of 2009 » more
-
Tuesday - October 27, 2009
Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:
Bayer back on the uptrend
HealthCare again strong – weak quarter at CropScience – MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million (plus 0.4 percent) / Net income EUR 249 million (minus 10.1 percent) / Net cash flow EUR 1,517 million (plus 22.9 percent) / Full-year Group forecast confirmed » more
-
Thursday - October 22, 2009
Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market » more
-
Friday - October 9, 2009
Improvement in orders
Bayer MaterialScience AG ends reduced working hours at German sites
Rates of pay to be raised again / Solidarity-based solution has proved its worth / Opening clause in collective agreement applied from February to the end of October 2009 » more
-
Monday - October 5, 2009
Phase-III data presented at the World Congress of Gynecology & Obstetrics (FIGO):
Bayer’s novel oral contraceptive Qlaira® significantly reduces heavy menstrual bleeding
Results also confirm significant improvement in blood iron levels » more
-
Wednesday - September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
First presentation of results at joint ECCO-ESMO congress in Berlin, Germany » more
-
Tuesday - September 22, 2009
Once again included in the Carbon Disclosure Leadership Index
Bayer honored as world’s best company in climate protection
Index organizer Dickinson: “Listed companies are the best placed to prosper in a low carbon economy of the future” / Bayer CEO Wenning: “Top position is high praise for our strategic alignment” / Investors and analysts specifically interested in companies' climate strategies » more
-
Thursday - September 17, 2009
Greater focus on future technologies:
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018
BioScience sales of EUR 1.4 billion targeted for 2018 / Biotech licensing agreements tap into business potential in excess of EUR 500 million / Peak sales potential of new crop protection actives raised to EUR 1.25 billion » more
-
Thursday - September 17, 2009
Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions » more
Search
Publications
Annual Report
Stockholders' Newsletter
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
Events
Download Center - Selection